NAD+ patches have become a popular alternative to capsules, injections, and intravenous infusions. Many products are also sold as multi-ingredient patches containing berberine, among other things, and in some cases also moringa. Their appeal is easy to understand. The patch is convenient, requires no swallowing of capsules or administering injections, and is often advertised as a way to deliver ingredients gradually and steadily over many hours.
However, convenience does not automatically mean effective delivery of substances to the body.
The most important scientific question is whether unmodified NAD+ can penetrate the skin in biologically significant amounts. This is important because the chemical properties of NAD+ hinder passive transdermal absorption more than those of many drugs effectively used in patches.
In this article, we explain how NAD+ patches are supposed to work, what transdermal pharmacology says about their potential absorption, why NAD+ is often combined with berberine, how such patches are typically used, and how their evidence base compares to capsules and injectable NAD+.
How are NAD+ transdermal patches supposed to work?
The transdermal patch is designed to enable the active substance to penetrate from the surface of the skin into deeper tissues, and ideally also into the systemic circulation.
The basic concept is simple.
Instead of swallowing the compound and subjecting it to the digestive tract, the active substance is placed in a skin patch that remains on it for several hours.
Manufacturers often claim that this method can ensure gradual absorption while bypassing degradation in the digestive tract.
Transdermal technology itself is not an experimental solution.
Well-known examples include nicotine patches, hormonal patches, and certain pain relief medications.
However, the efficacy of transdermal delivery depends largely on the chemical properties of the specific molecule.
Some substances pass through the skin relatively easily.
Others penetrate it only very slightly.
This distinction is particularly important in the case of NAD+.
The fact that the patch is effective for nicotine does not mean that the same simple delivery mechanism will be equally effective for the NAD+ molecule, which is much larger and highly water-soluble.
Does NAD+ from the patch actually penetrate the skin?
Direct data showing significant absorption of NAD+ from ordinary passive adhesive patches is currently very limited.
This is the main weakness of the evidence base for this product category.
A problem related to particle size
The skin has evolved to function as a barrier.
Its outermost layer, the stratum corneum of the epidermis, limits the penetration of many substances from the external environment into the body.
One of the principles frequently cited in research on transdermal delivery is the so-called 500-dalton rule. [1]
In accordance with this general assumption, molecules penetrating through undamaged skin via passive diffusion typically have a mass of less than approximately 500 daltons and, at the same time, favorable chemical properties, including adequate lipid solubility.
This is not an absolute right.
However, it serves as a useful starting point for assessing whether a given substance is naturally suitable for passive transdermal delivery.
The molecular mass of NAD+ is approximately 663 Daltons. [2]
This means that it exceeds the commonly accepted threshold for passive diffusion.
NAD+ also poses a second problem.
It is a strongly polar, charged, and highly water-soluble molecule, rather than a small, fat-soluble compound.
The stratum corneum of the skin is particularly effective at limiting the passage of large and strongly hydrophilic molecules.
The combination of NAD+’s relatively high molecular weight and its high polarity thus provides a pharmacologically sound basis for questioning whether significant amounts of unchanged NAD+ can penetrate healthy skin using a standard adhesive patch.
This does not mean that absorption is impossible.
It means, however, that effective delivery must be directly demonstrated rather than merely assumed.
Can transdermal absorption be increased?
Yes.
Various technologies have been developed to improve the delivery of substances that, on their own, do not penetrate the skin well.
These include iontophoresis, microneedle systems, chemical penetration enhancers, ultrasound-based methods, and other specialized technologies.
Iontophoresis uses a small electric current to facilitate the movement of charged particles through the skin.
This is of particular importance for NAD+, as the main published human study on transdermal NAD+ used iontophoresis rather than a simple passive patch. [3]
The study included individuals with persistent fatigue following COVID-19.
Participants received NAD+ via iontophoresis patches in combination with low-dose oral naltrexone.
Researchers reported an improvement in fatigue indices and quality of life.
However, the study does not allow us to conclude that the NAD+ patch was responsible for this improvement.
It was an open-label study, did not include a placebo group, and involved two interventions simultaneously.
The very fact that iontophoresis was used is also significant, as it means that the results cannot be considered proof of the effectiveness of ordinary passive NAD+ patches sold online.
Electrically assisted patches and standard adhesive patches are different delivery systems from a pharmacological perspective.
What about standard commercial NAD+ patches?
Many consumer NAD+ patches appear to rely primarily on the passive diffusion of ingredients from the adhesive layer.
Product descriptions do not always clearly indicate whether specialized penetration-enhancing technologies were used.
A lack of such formulation details makes comparing products difficult.
Most importantly, no published controlled human study has been identified that used a typical passive NAD+ patch and subsequently demonstrated a significant increase in blood or tissue NAD+ compared to placebo.
This is precisely the most important missing information.
Without direct pharmacokinetic measurements, it is unknown how much unchanged NAD+, if any, enters the systemic circulation from such products.
Current evidence therefore justifies caution.
NAD+ patches are commercially available, but effective passive delivery of unmodified NAD+ through the skin has not been convincingly demonstrated in controlled human studies.
Why are NAD+ and berberine combined in a single patch?
NAD+ and berberine are often combined because both compounds appear in research on metabolism and longevity, although they operate through very different biological mechanisms.
Berberine is a plant-derived alkaloid found in several plants traditionally used in herbal medicine.
Contemporary scientific literature on berberine focuses mainly on glucose regulation, lipid metabolism, insulin sensitivity, and related metabolic pathways.
One of the most frequently discussed mechanisms is AMPK, or AMP-activated protein kinase.
AMPK acts as an important cellular energy status sensor.
NAD+, on the other hand, acts as a coenzyme in energy metabolism and is required by NAD+-dependent enzymes, such as sirtuins.
Since both the AMPK and sirtuin pathways are involved in the broad regulation of cellular energy metabolism, the combination of berberine and NAD+ may appear to be biologically complementary.
However, this is a mechanistic explanation.
This is not proof of synergy.
No controlled human study has been identified that specifically evaluates a transdermal patch containing NAD+ and berberine.
Claims that these two ingredients work better together in a patch are therefore not currently supported by direct clinical studies.
This comparison also makes sense from a marketing perspective.
Both compounds are often promoted in terms of metabolic health, anti-aging, cellular energy, and longevity.
Combining them into a single product allows the manufacturer to address several related wellness topics at once.
However, the question of the effectiveness of transdermal delivery should be evaluated separately for each ingredient.
Berberine and Transdermal Delivery
Berberine is a much smaller molecule than NAD+.
Depending on the specific chemical form, commonly used berberine salts have a molecular weight ranging from approximately 336 to 390 daltons.
This means that from the perspective of size alone, they are below the 500-dalton threshold frequently discussed in the context of passive transdermal permeation.
However, molecular weight in itself does not guarantee effective skin absorption.
Lipophilicity, degree of ionization, formulation, concentration, skin condition, and the patch technology used are also important factors.
The most important thing, then, is that the same patch does not necessarily deliver NAD+ and berberine with the same effectiveness.
Their chemical properties differ significantly.
The presence of both ingredients on the label does not, therefore, prove that each of them enters the systemic circulation in a significant or comparable amount.
How are NAD+ patches usually applied?
There is no standardized and clinically validated protocol for the use of NAD+ patches comparable to the information contained in the summary of product characteristics for an approved transdermal drug.
Commercial instructions vary by manufacturer.
The information below describes typical manufacturer practices, not an approved clinical protocol for NAD+.
Application Site
Manufacturers usually recommend applying the patch to relatively clean, dry, and hairless skin.
The most commonly suggested sites include the upper arm, shoulder, abdomen, or thigh.
The primary goal is to ensure that the patch adheres well and maintains stable contact with the skin.
It is generally best to avoid applying the product to damaged or irritated skin.
Broken skin integrity can increase irritation and at the same time unpredictably alter absorption.
How long to wear the patch
The recommended wearing time varies significantly between products.
Some manufacturers recommend a few hours.
Others suggest leaving the patch on for most of the day or even up to about 24 hours.
These periods are usually set by the manufacturer.
They should not be interpreted as pharmacokinetically validated NAD+ delivery periods unless the specific formulation has been directly tested.
Currently, there is little published data determining how quickly unmodified NAD+ could enter the circulation from a passive patch, when the systemic concentration would reach a maximum, or how long it would remain at an elevated level.
Changing the Application's Location
It is often recommended to rotate the patch application site.
Regularly applying the adhesive layer to the same area of skin may increase the risk of local irritation.
The same rule also applies to approved transdermal products, such as nicotine patches.
However, changing the location does not increase the evidence for NAD+ absorption.
It is primarily a practical way to limit repeated contact of the adhesive with the same area of skin.
Skin condition
Patches are usually intended for application on intact skin.
Recently shaved, inflamed, damaged, sunburned, or otherwise irritated skin may be more sensitive to the adhesive and may also alter absorption.
Since detailed pharmacokinetic data on NAD+ patches remain limited, product-specific instructions should take precedence over assumptions based on other transdermal systems.
NAD+ patches vs capsules vs injections: which form delivers more?
There is currently no strong human head-to-head study comparing NAD+ patches, oral NAD+ precursors, and injectable NAD+ under identical conditions.
However, the quality of evidence for the individual routes of administration varies significantly.
Oral capsules and tablets
Oral products containing NAD+ precursors, such as NR and NMN, currently have the strongest human research base.
Numerous randomized, placebo-controlled trials have shown that oral NR and NMN can increase circulating NAD+ or its associated metabolites. [4]
This does not prove that these compounds improve every health parameter associated with NAD+ biology.
Their impact on NAD+-related biomarkers has, however, been confirmed multiple times.
Injectable and intravenous NAD+
Injections and IV infusions bypass the gastrointestinal tract.
From the perspective of the delivery method, this is a relatively simple solution.
However, controlled evidence regarding clinical outcomes in wellness and anti-aging applications remains limited.
A 2026 systematic review found no eligible controlled trials regarding intravenous or intramuscular NAD+ specifically for anti-aging or general wellness applications. [5]
The commercial popularity of IV NAD+ therapy thus currently outweighs the strength of controlled clinical evidence supporting these applications.
NAD+ Transdermal Patches
The patches face an additional problem.
Unlike IV administration, which delivers NAD+ directly into the bloodstream, a passive patch must first allow the molecule to pass through the skin barrier.
The relatively high molecular weight of NAD+ and its high polarity hinder this process from a basic pharmacological standpoint.
One key human study used iontophoresis instead of a standard passive patch. [3]
At the same time, NAD+ was used in it along with a low dose of naltrexone, and the study did not have a placebo group.
In the case of regular adhesive patches, no controlled human studies have been identified demonstrating a reliable increase in NAD+ in blood or tissues.
Based on current evidence, oral NAD+ precursors have significantly stronger support for measurably increasing NAD+ than passive transdermal patches.
NAD+ Patches vs Capsules vs IV — Comparison
| Feature | NAD+ Patches | Oral NR/NMN | Injectable/IV NAD+ |
|---|---|---|---|
| Main ingredient | Usually NAD+, sometimes combinations | NAD+ precursors | NAD+ |
| Application route | Through the skin | Absorption from the gastrointestinal tract | Injection or directly into the bloodstream |
| Omija digestion | Yes, if it is absorbed | Not | Yes |
| The main barrier to absorption | Skin | Gastrointestinal tract | No skin or gastrointestinal barrier |
| Strong human biomarker data | Not determined for passive patches | Yes | Limited to common wellness protocols |
| Randomized human trials | Very limited | The strongest base among these forms | Limited |
| Tests Using Iontophoresis | Yes, one small study with limitations [3] | Not applicable | Not applicable |
| Pharmacokinetics of a passive patch | Not established | Not applicable | Not applicable |
| Requires a clinic | Usually not | Not | Usually yes |
| Proof of delivery | Not | The increase in NAD+ has been demonstrated | Direct administration, but clinical superiority has not been demonstrated |
Therefore, the most important question regarding patches is not whether transdermal delivery can work at all.
The question is whether this specific molecule can be delivered in a significant amount by a specific formulation.
In the case of standard NAD+ patches, this remains insufficiently proven.
What Do Reviews of NAD+ Patches Really Say?
Consumer reviews of NAD+ patches often describe subjective changes in energy, mood, fatigue, concentration, or general well-being.
In the case of NAD+ patches with berberine, some reviews also mention appetite or metabolism.
Such experiences can be meaningful to the person describing them.
However, they do not constitute evidence of pharmacological absorption or clinical efficacy.
Why are user reviews difficult to interpret?
Consumer experiences are not collected under controlled conditions.
There is usually no placebo group.
The person knows that they are using the product.
At the same time, other factors—such as supplements, medications, diet, sleep quality, physical activity, caffeine intake, and your natural mood—may vary from day to day.
Expectations can also influence the subjective assessment of factors such as energy levels, mood, or fatigue.
Another problem is the selection of people publishing reviews.
People who have had very positive or very negative experiences may be more likely to leave a review than those who did not notice a significant difference.
Product reviews therefore provide information on consumer experiences.
They do not prove that unaltered NAD+ penetrated the skin or that it increased cellular NAD+ levels.
This is particularly significant because the chemistry of NAD+ itself already raises doubts about its passive permeability through the skin.
A positive user review cannot resolve this pharmacological uncertainty.
To demonstrate actual absorption, researchers would need to measure NAD+ or relevant metabolites in the blood or tissues after applying the patch and compare the results with a placebo under controlled conditions.
Such studies for standard passive NAD+ patches are still largely lacking.
Frequently Asked Questions About NAD+ Patches
Do NAD+ patches really work?
It has not been clearly demonstrated that ordinary passive NAD+ patches deliver significant amounts of unchanged NAD+ through human skin.
NAD+ has a mass greater than approximately 500 daltons—a value often cited as the practical limit for passive transdermal permeation—and is also highly polar. [1,2]
There is a lack of direct pharmacokinetic studies of typical consumer patches.
Can NAD+ be absorbed through the skin?
Potentially yes, but the delivery technology matters a lot.
In one human study, iontophoresis was used to facilitate the transdermal delivery of NAD+. [3]
This does not prove that absorption is equivalent to that from simple adhesive patches without an active penetration-enhancing system.
What is the 500-dalton rule?
The 500-dalton rule is a frequently cited principle in transdermal delivery science, according to which passive skin penetration becomes increasingly difficult for molecules larger than about 500 daltons. [1]
This is not an absolute limit.
However, it is a useful criterion for assessing the likelihood of effective passive absorption.
NAD+ has a molecular mass of approximately 663 daltons. [2]
Is there scientific evidence supporting NAD+ patches with berberine?
There is no dedicated clinical trial in humans demonstrating a synergistic effect of a patch containing NAD+ and berberine.
Both ingredients have distinct biological rationales, but their combination in a single patch has not been clinically confirmed.
Does berberine penetrate the skin more easily than NAD+?
Its lower molecular weight makes passive transdermal absorption more likely simply because of the size of the molecule.
However, effective absorption through the skin depends on many other factors.
To determine exactly how much berberine a particular patch actually delivers, an appropriate pharmacokinetic study would still be needed.
Are NAD+ patches better than capsules?
This has not been demonstrated.
Oral NR and NMN have significantly stronger randomized human data showing a measurable increase in NAD+-related biomarkers. [4]
Comparable data is lacking for standard passive NAD+ patches.
Are NAD+ patches better than IV NAD+?
There is no direct human study to confirm this.
An IV infusion bypasses the skin barrier and delivers NAD+ directly into the bloodstream, whereas a patch requires absorption through the skin.
At the same time, IV NAD+ also has limited controlled data on clinical outcomes in anti-aging and wellness applications. [5]
Can consumer reviews prove that the patch is absorbed?
No.
Reviews may describe subjective experiences, but they cannot demonstrate systemic absorption, blood concentration, or changes in cellular NAD+.
Answering these questions requires controlled pharmacokinetic studies.
Limitations of current evidence
The greatest limitation is the lack of direct human pharmacokinetic data regarding ordinary passive NAD+ patches.
No controlled study measuring NAD+ in blood or tissues after applying a simple adhesive patch of the type commonly offered to consumers has been identified.
The main question concerning absorption thus remains unresolved.
Another limitation is the available human transdermal study.
It utilized iontophoresis, which is an active delivery method rather than simple passive diffusion. [3]
Participants also received an oral low dose of naltrexone.
The study was open-label and did not have a placebo group.
Therefore, it does not allow to determine whether the same NAD+ was responsible for the observed improvement.
The third limitation is products combining NAD+ and berberine.
No dedicated clinical study evaluating such a combination in patch form has been identified.
Separate studies on NAD+ biology and berberine metabolism should not be combined and presented as evidence supporting the synergistic effect of the transdermal mixture.
The 500 dalton rule also has its limitations.
It is a general guideline, not an absolute physical barrier. [1]
Advanced formulation technologies can enhance the skin delivery of substances that would otherwise penetrate poorly.
However, it is often unclear whether specific commercial NAD+ patches actually use such technologies and whether they deliver clinically significant amounts of NAD+.
Finally, consumer reviews represent a poor source of information on absorption.
Subjective reports do not allow distinguishing between a pharmacological effect and placebo, natural changes in well-being, simultaneous lifestyle changes, the effects of other patch ingredients, or selection bias among people publishing reviews.
Current evidence therefore justifies describing passive NAD+ patches as a convenient yet poorly validated delivery method whose ability to significantly increase systemic NAD+ has not yet been convincingly demonstrated.
Disclaimer
This article is for educational and scientific-informational purposes only. It does not constitute medical advice, therapeutic recommendations, dosing instructions, product selection recommendations, or recommendations for the use of NAD+ patches, berberine patches, products combining NAD+ with berberine, or any other transdermal supplements.
The mere commercial availability of the NAD+ patch does not prove that unaltered NAD+ is absorbed through the skin in quantities of clinical significance. Results concerning iontophoresis-assisted delivery should also not be automatically extrapolated to standard passive adhesive patches, as these are different technologies.
NAD+, berberine, and patch products combining these ingredients are not approved by the FDA or EMA to treat, prevent, or cure diseases. Claims regarding increased energy, anti-aging effects, improved metabolism, detoxification, or disease treatment should be evaluated independently of data confirming skin absorption alone.
Pregnant or breastfeeding individuals, people with diabetes or other significant metabolic disorders, and those taking glucose-lowering medications, cardiovascular drugs, anticoagulants, or other prescription medications should discuss the use of products containing berberine or NAD+ with a qualified healthcare professional. Persistent skin irritation or other unexpected symptoms after using the patch also require proper evaluation.
References
[1] Bos, J. D., & Meinardi, M. M. H. M. (2000). The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Experimental Dermatology, 9(3), 165–169. https://doi.org/10.1034/j.1600-0625.2000.009003165.x
[2] Yoshino, J., Baur, J. A., & Imai, S. (2018). NAD+ intermediates: The biology and therapeutic potential of NMN and NR. Cell Metabolism, 27(3), 513–528. https://doi.org/10.1016/j.cmet.2017.11.002
[3] Isman, A., Nyquist, A., Strecker, B., Harinath, G., Lee, V., Zhang, X., & Zalzala, S. (2024). Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19. Brain, Behavior, & Immunity – Health, 36, 100733. https://doi.org/10.1016/j.bbih.2024.100733
[4] Yi, L., Maier, A. B., Tao, R., Lin, Z., Vaidya, A., Pendse, S., Thasma, S., Andhalkar, N., Avhad, G., & Kumbhar, V. (2022). The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: A randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience, 45, 29–43. https://doi.org/10.1007/s11357-022-00705-1
[5] Gallagher, C., & Emmanuel, O. O. (2026). NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Research Reviews, 116, 103057. https://doi.org/10.1016/j.arr.2026.103057